B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.

Front Immunol · 2026 · PMC12996067 · PMID 41859124

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Similarly, Remibrutinib significantly improved EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) scores and showed a trend towards improvement in salivary flow rates in a Phase II randomized controlled trial in pSS ( 143 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.